

09/640935

C9C

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


Applicant(s): Kinch et al.:

Patent No.: 6,927,203 B1

Issued: August 9, 2005

Title: TREATMENT OF METASTATIC DISEASE

Docket No. 290.00100101



**Certificate  
of Correction**  
DEC 14 2005

**Attention Certificate of Correction Branch**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

- ☒ An itemized return postcard.
- ☐ A Petition for Extension of Time for \_\_ month(s) and a check in the amount of \$\_\_ for the required fee.
- ☐ An Information Disclosure Statement (\_\_ pgs); copies of \_\_ applications; 1449 forms (\_\_ pgs); and copies of \_\_ documents cited on the 1449 forms.
- ☐ A request for continued examination (RCE) and a check in the amount of \$\_ for the required filing fee.
- ☐ An Appeal Brief and a check in the amount of \$\_\_, for the required Appeal Brief filing fee.
- ☐ A check in the amount of \$\_\_, for \_\_.
- ☐ A certified copy of a \_\_ application, Serial No. \_\_, filed \_\_\_\_, the right of priority of which is claimed under 35 U.S.C. §119.
- ☒ Other: Request for Certificate of Correction (2 pages), Certificate of Correction (2 pages, in duplicate)
- ☐ Amendment \_\_ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$50 =	
Independent Claims				x \$200 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$360 Here →					
Total Additional Claim Fees Required					

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

**CERTIFICATE UNDER 37 C.F.R. §1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: **Attention Certificate of Correction Branch**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 7<sup>th</sup> day of December, 2005.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813

By:

Victoria A. Sandberg

Reg. No.: 41,287

Direct Dial: 612-305-1226

Facsimile: 612-305-1228

(LARGE ENTITY TRANSMITTAL UNDER RULE 1.8)

DEC 14 2005



PATENT  
Docket No. 290.00100101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kinch et al. )  
Patent No.: 6,927,203 B1 )  
Issued: August 9, 2005 )  
For: TREATMENT OF METASTATIC DISEASE

REQUEST FOR CERTIFICATE OF CORRECTION

Attention Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

A Certificate of Correction is requested to be issued correcting printing errors appearing in the above-identified United States patent. Two copies of the text noting the corrections for the Certificate are enclosed. Since none of the errors listed are due to Applicants' mistake, no fee is necessary for the Certificate. The corrections in the proposed Certificate of Correction do not involve such changes in the patent as would constitute new matter or would require reexamination.

Please mail the printed Certificate of Correction to the undersigned attorney.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 7<sup>th</sup> day of December, 2005.




Date

December 7, 2005

Respectfully submitted  
By  
Mueting, Raasch & Gebhardt, P.A.  
P.O. Box 581415  
Minneapolis, MN 55458-1415  
Phone: (612)305-1220  
Facsimile: (612)305-1228  
Customer Number 26813

By:

  
Victoria A. Sandberg  
Reg. No. 41,287  
Direct Dial (612)305-1226

DEC 14 2005

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 6,927,203 B1

DATED: August 9, 2005

INVENTOR(S): Kinch et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Title, delete, "TREATMENT OF METASTATIC DISEASE" and insert –EPHA2 AS A THERAPEUTIC TARGET FOR CANCER–

On page 3, after "Hess et al., "Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (ECK/EphA2)," *Cancer Res.*", delete "2001; 61–3250-3255" and insert –2001;61:3250-3255–.

On page 3, after Jakobovits et al., "Germ-like transmission and expression of a", delete "humid-derived" and insert –human-derived–.

On page 3, after Khosravi-Far et al. "Activation of Rac1, RhoA, and Mitogen-Activated Protein Kinases Is Required for Ras Transformation" *Molecular and Cellular Biology* 1995;", delete "15(1)" and insert –15(11)–.

On page 4, after "O'Brien et al., "A mechanism for trabecular meshwork cell retraction: Ethacrynic acid initiates the", delete "dephosphorylation" and insert –dephosphorylation–.

MAILING ADDRESS OF SENDER:

PATENT NO. 6,927,203 B1

MUETING, RAASCH & GEBHARDT, P.A.  
P.O. BOX 581415  
MINNEAPOLIS, MINNESOTA 55401  
Customer Number 26813

No. of add'l copies

DEC 14 2005

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 6,927,203 B1

DATED: August 9, 2005

INVENTOR(S): Kinch et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 4, delete "Ogawa et al. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization." *Oncogene*. 2000; 19(52):6043-52. Dec. 7." and insert –Ogawa et al. "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization." *Oncogene*. 2000; 19(52):6043-52.–

In column 8, line 66, delete "34" and insert –3-4–.

In column 12, line 28, delete MCF<sup>EphA2</sup> and insert – MCF-10A–.

MAILING ADDRESS OF SENDER:

PATENT NO. 6,927,203 B1

MUETING, RAASCH & GEBHARDT, P.A.  
P.O. BOX 581415  
MINNEAPOLIS, MINNESOTA 55401  
Customer Number 26813

No. of add'l copies

DEC 14 2005

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 6,927,203 B1

DATED: August 9, 2005

INVENTOR(S): Kinch et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Title, delete, "TREATMENT OF METASTATIC DISEASE" and insert –EPHA2 AS A THERAPEUTIC TARGET FOR CANCER–

On page 3, after "Hess et al., "Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (ECK/EphA2)," *Cancer Res.*", delete "2001; 61–3250-3255" and insert –2001;61:3250-3255–.

On page 3, after Jakobovits et al., "Germ-like transmission and expression of a", delete "humid-derived" and insert –human-derived–.

On page 3, after Khosravi-Far et al. "Activation of Rac1, RhoA, and Mitogen-Activated Protein Kinases Is Required for Ras Transformation" *Molecular and Cellular Biology* 1995;", delete "15(1)" and insert –15(11)–.

On page 4, after "O'Brien et al., "A mechanism for trabecular meshwork cell retraction: Ethacrynic acid initiates the", delete "dephosphorylation" and insert –dephosphorylation–.

MAILING ADDRESS OF SENDER:

PATENT NO. 6,927,203 B1

MUETING, RAASCH & GEBHARDT, P.A.  
P.O. BOX 581415  
MINNEAPOLIS, MINNESOTA 55401  
Customer Number 26813

No. of add'l copies

DEC 14 2005

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO.: 6,927,203 B1

DATED: August 9, 2005

INVENTOR(S): Kinch et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 4, delete "Ogawa et al. The ephrin-A1 ligand and its receptor. EphA2, are expressed during tumor neovascularization." *Oncogene*. 2000; 19(52):6043-52. Dec. 7." and insert –Ogawa et al. "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization." *Oncogene*. 2000; 19(52):6043-52.–

In column 8, line 66, delete "34" and insert –3-4–.

In column 12, line 28, delete MCF<sup>EphA2</sup> and insert – MCF-10A–.

MAILING ADDRESS OF SENDER:

PATENT NO. 6,927,203 B1

MUETING, RAASCH & GEBHARDT, P.A.  
P.O. BOX 581415  
MINNEAPOLIS, MINNESOTA 55401  
Customer Number 26813

No. of add'l copies

DEC 14 2005